GlassScriptPhysician profile
Scott W Oberhoff
NPI 1528250149
$11,815.36
in general payments reported to CMS, 2019-2025
31 companies · $3,167 in 2025
The $3,167 reported for 2025 was more than what 77% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,258 · 2020: $937 · 2021: $1,283 · 2022: $855 · 2023: $1,259 · 2024: $3,056 · 2025: $3,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,650 · Consulting Fee: $2,798 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,650.31 |
| Consulting Fee | $2,797.61 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,517.21 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,635.96 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,402.26 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Csl Behring | $855.82 | 2019-2025 | Hizentra, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $711.75 | 2020-2025 | Cuvitru, Eohilia |
| Regeneron Healthcare Solutions, INC. | $599.76 | 2019-2025 | Dupixent |
| Amgen INC. | $451.05 | 2022-2025 | Tezspire |
| Octapharma USA, INC. | $415.47 | 2019-2025 | Cutaquig, Octagam Immune Globulin (Human) |
| Genentech USA, INC. | $359.47 | 2020-2025 | Xolair |
| Grifols USA, LLC | $264.72 | 2019-2025 | Xembify, Gamunex-C |
| Pfizer INC. | $202.96 | 2020-2025 | |
| Pharming Healthcare, INC. | $174.72 | 2020-2025 | Ruconest |
| Shire North American Group INC | $166.75 | 2019 | |
| Abbvie INC. | $148.86 | 2022-2024 | |
| Kaleo, INC. | $143.78 | 2019-2024 | Auvi-Q |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $138.45 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Teva Pharmaceuticals USA, INC. | $112.84 | 2019-2021 | |
| Mylan Specialty L.P. | $92.28 | 2020-2023 | Yupelri |
| Adma Biomanufacturing LLC | $72.32 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $67.46 | 2025 | |
| Ionis Pharmaceuticals, INC. | $51.74 | 2025 | Dawnzera |
| Hospira, INC. | $42.51 | 2024 | |
| Organon LLC | $29.44 | 2025 | |
| Optinose US, INC. | $25.77 | 2025 | |
| Verona Pharma, INC. | $23.03 | 2025 | Ohtuvayre |
| Leo Pharma INC. | $23.00 | 2025 | Adbry |
| Biocryst Pharmaceuticals, INC. | $20.43 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $18.43 | 2025 | Neffy |
| Jazz Pharmaceuticals INC. | $17.11 | 2019 | |
| Mylan Pharmaceuticals INC. | $16.80 | 2019 | |
| Phadia US INC. | $13.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Oberhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.